Treatment of Diabetic Macular Edema with Intravitreal Antivascular Endothelial Growth Factor and Prompt versus Deferred Focal Laser during Long-Term Follow-Up and Identification of Prognostic Retinal Markers

Figure 3

Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in eyes with diabetic macular edema (DME) treated with intravitreal antivascular endothelial growth factor (anti-VEGF) and focal macular laser. Data represent eyes revealing clusters of intraretinal hyperreflective material as detected on spectral domain optical coherence tomography (SD-OCT) and eyes without these morphological changes. BCVA in eyes with clusters of hyperreflective foci in the central macular region detected by SD-OCT was significantly inferior compared with eyes without intraretinal hyperreflective foci at year 5 of follow-up (0.39; 20/50 Snellen (SD = 0.25, 0.4 logMAR) versus 0.63; 20/32 Snellen (SD = 0.22, 0.2 logMAR), ). BCVA = best-corrected visual acuity. CRT = central retinal thickness. Black lines represent trend lines. Stars indicate standard deviation. values indicate change compared with baseline. (a) BCVA in eyes with (22 eyes) and without (20 eyes, light blue line) intraretinal hypherreflective foci in SD-OCT. (b) CRT in eyes with (22 eyes) and without (28 eyes, light green line) intraretinal hypherreflective foci in SD-OCT.